Preemptive Analgesia With OxyContin Versus Placebo Before Surgery for Long Bone Fractures

Sponsor
Rambam Health Care Campus (Other)
Overall Status
Completed
CT.gov ID
NCT00254631
Collaborator
(none)
65
1
2
20
3.2

Study Details

Study Description

Brief Summary

We would like to check whether pre-operative administration of an oral controlled-release opioid formulation (Oxycodone hydrochloride (OxyContin)) could result in a clear effect of preemptive analgesia.

Condition or Disease Intervention/Treatment Phase
  • Drug: Oxycodone hydrochloride
Phase 4

Detailed Description

Preemptive analgesia is based on the concept of treating pain before inflicting the painful stimulus. One suggested mechanism is that transmission of pain signals is altered when the patient is treated before infliction of noxious stimulation. That prevents changes from happening in the nervous system, making transformation from acute to chronic pain ("central sensitization") less likely, and thus reducing post operative pain.

Clinically, good post operative pain control has been shown to be an effective method for hastening patient convalescence and discharge. It makes part of a general approach aiming to accelerate surgical recovery through earlier enteric feeding and ambulation

OxyContin tablets deliver Oxycodone at a controlled release manner, over 12 hours. After oral administration oral bioavailability is 60-87%.

A biphasic absorption pattern is observed, describing the initial (0.6 hours) and prolonged (6.9 hours) release of Oxycodone from the OxyContin tablets. Clinical analgesia is observed within 1 hour of administration.

We believe that this mode of oral drug release is more appropriate for the perioperative pain treatment of patients undergoing short to medium term operations: with timely administration, the first absorbed part of the drug reaches the plasma before infliction of the noxious stimuli, possibly counteracting primary sensitization, and the second part absorbed, acts on post operative ongoing pain, possibly counteracting more advanced stages of neuronal plasticity.

Study Hypothesis:

Our hypothesis is that post operative pain will be lowered by pre-operative administration of OxyContin. When comparing the two groups we will look for differences in observed parameters, especially VAS numbers, time to first analgesic request, post operative analgesic requirements, time to first oral intake and length of hospitalization, to confirm or deny our hypothesis.

Study Design

Study Type:
Interventional
Actual Enrollment :
65 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Care Provider, Investigator)
Primary Purpose:
Treatment
Official Title:
Preemptive Analgesia With OxyContin Versus Placebo Before Surgery for Long Bone Fractures
Study Start Date :
Apr 1, 2007
Actual Primary Completion Date :
Dec 1, 2008
Actual Study Completion Date :
Dec 1, 2008

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: study group

pre operative medication with 20 mg oxycontine PO

Drug: Oxycodone hydrochloride

Placebo Comparator: placebo group

pre operative medication with placebo tablet PO

Outcome Measures

Primary Outcome Measures

  1. post operative pain scores during first 24 hours (Visual analog scale) [24 hours after surgery]

Secondary Outcome Measures

  1. Time to first analgesic request [at PACU]

  2. Total other pain medications at first 24 hours post operative [first 24 hours after surgery]

  3. Time to first oral intake [first 24 hours after surgery]

  4. Length of hospitalization [after surgery]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Patient consent.

  2. Age 18 years to 60 years.

  3. Isolated limb bone fracture/s.

Exclusion Criteria:
  1. Patient refusal.

  2. Age 61 years and older.

  3. Known allergy to study medication.

  4. Multiple bone fractures in different limbs.

  5. Multiple trauma.

  6. Oncological patients.

  7. Respiratory depression / respiratory insufficiency / hypercarbia.

  8. Acute bronchial asthma.

  9. CNS depression / hallucinations.

  10. Alzheimer / dementia.

  11. Known convulsive disorder.

  12. Prostate hypertrophy.

  13. Paralytic ileus.

  14. Renal dysfunction (plasma creatinine > 1.5).

  15. Liver dysfunction.

  16. Adrenocortical insufficiency.

  17. Hypothyroidism.

  18. Pancreatitis.

  19. Pregnancy and lactating.

  20. Drug abuse, current or in the past.

  21. Alcohol abuse on admission to operating room.

Contacts and Locations

Locations

Site City State Country Postal Code
1 RAMBAM Health Care Campus Haifa Israel 31096

Sponsors and Collaborators

  • Rambam Health Care Campus

Investigators

  • Principal Investigator: Ruth Edery, MD, Rambam Health Care Campus

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
edery, Rambam Health Care Campus, Rambam Health Care Campus
ClinicalTrials.gov Identifier:
NCT00254631
Other Study ID Numbers:
  • pre-oxy.CTIL
First Posted:
Nov 16, 2005
Last Update Posted:
Feb 5, 2015
Last Verified:
Feb 1, 2015
Keywords provided by edery, Rambam Health Care Campus, Rambam Health Care Campus
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 5, 2015